医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

 Genetron Health Announces Strategic Collaboration with CStone

2019年12月13日 PM11:05
このエントリーをはてなブックマークに追加


 

BEIJING

Recently, Genetron Health has announced strategic collaboration with CStone Pharmaceuticals (“CStone”), providing companion diagnostic development services and clinical sample testing services for the oncological targeting pharmaceutical R&D of CStone, in order to boost efficiency of new medicine development and its approval processes.

Based on diverse testing platforms, independently researched and developed bioinformatics analysis platforms, vast databases as well as consistent and efficient innovative abilities supported by the multi-disciplinary research team, Genetron Health has registered multiple patents, including ‘One-Step Seq Method,’ and obtained NMPA approvals of various IVD devices and assays, which has led to accumulation of extensive R&D experience and registration applications with NMPA. Moreover, benefiting from its world-leading quality management system and rich clinical partnership resources, Genetron Health has established a full-cycle pharmaceutical R&D service system, which is capable of providing standardized full-chain services for its partners, consisting of multinational pharmaceutical companies, innovative pharmaceutical companies and biomedical CROs in the fields including early stage biomarker development, RWS, molecular testing for clinical trials, patient recruitment and filtering, and companion diagnostic development and commercialization.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191213005208/en/

CONTACT

Media:

Genetron Health

TAO Yuan

Email: yuan.tao@genetronhealth.com

同じカテゴリーの記事 

  • 领先的合同开发和制造组织PCI Pharma Services发布首份综合ESG报告
  • EverEx Secures iF Design Award for “MORA,” a Leading Musculoskeletal Rehabilitation Solution
  • Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
  • SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
  • Oriola Partners With HCLTech to Enhance Customer Experience Through Digital Transformation